TERN Terns Pharmaceuticals

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens JMP Life Sciences Conference 2024 on Tuesday, May 14, 2024 at 1:30 p.m. ET.

A live webcast of the fireside chat will be available on the investor relations page of the Terns Pharmaceuticals website at . A replay of the webcast will be archived on Terns’ website for 30 days following the event.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator program. For more information, please visit: .

Contacts for Terns

Investors

Justin Ng

 

Media

Jenna Urban

Berry & Company Public Relations

 

 



EN
07/05/2024

Underlying

TERNTerns Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Terns Pharmaceuticals

 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a virtual fireside chat at UBS Obesity Therapeutics Day on Thursday, May 23, 2024 at 1:00 p.m. ET. A live webcast of the fireside chat will be available on...

May 17, 2024 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and...

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in 2H24 Cash, cash equivalents and marketable securities of $241 million, expected to provide runway into 2026 FOSTER CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical stage biopharmaceutical company developing...

May 13, 2024 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Announces Leadership Changes

Terns Pharmaceuticals Announces Leadership Changes FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Scott Harris as chief development officer (CDO) effective May 28, 2024 and the upcoming departure of Erin Quirk, M.D., president, head of research and development. Dr. Quirk will be transitioning her responsibilities and...

May 8, 2024 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences...

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024 FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens JMP Life Sciences Conference 2024 on Tuesday, May 14, 2024 at 1:30 p.m. ET. A live webcast of the fireside chat...

May 7, 2024 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under N...

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2024 an equity inducement award to Melita Sun Jung, the Company’s new Chief Business Officer, under the terms of the 2022 Employment Inducement Award Plan, a...

May 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch